1. Scrip
  2. >>Business

Key Wins In US By Indian Firms - Keep An Eye On These In 2019

 
• By Anju Ghangurde

2018 saw front-line Indian companies receive some key product approvals in the US or sew up large or niche M&A transactions there. How these play out could have a material impact on the growth outlook of these firms in 2019. 

Dollar - Rupee
KEY PRODUCT APPROVALS AND DEALS IN THE US COULD SHAPE 2019 FOR LARGE INDIAN FIRMS

It has been an eventful 2018 for India Pharma Inc in the US, to say the least. Among some interesting wins during the year were high profile product launches, including a partnered biosimilar from Biocon Ltd.’s stable that hit the US market, and the largest out-bound M&A deal by an Indian pharma company, which saw Aurobindo Pharma Ltd. snap up certain parts of Sandoz International GMBH’s US portfolio.

The impact of some of these events, such as the Aurobindo-Sandoz deal or then Sun Pharmaceutical Industries Ltd.’s launch...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Executives On The Move: Changes At The Top At Novo Nordisk Plus Other New CEOs

Flashpoint Therapeutics and Nerviano Medical Sciences (Shanghai) have new leaders, while Genmab hires an ex-Gilead Sciences executive.

Lilly Confident In Orforglipron Despite Disappointing Phase III Data

 
• By Mandy Jackson

Lilly spent much of its earnings call defending orforglipron as analysts lamented its results in obesity versus Novo’s semaglutide, overshadowing strong Q2 revenue growth driven by existing GLP-1/GIP franchise Mounjaro/Zepbound.

Competition Weighs On Gilead’s CAR-Ts As Both See Sales Decline

 
• By Alaric DeArment

The quarter saw strong growth overall, but the company now expects sales of Yescarta and Tecartus to fall for the full year 2025 versus 2024 thanks to competition.